Skip to content

Long-term Outcomes of Upfront Pancreatectomy with Venous Resection for Pancreatic Cancer: A Single-Center, Retrospective Analysis

Long-term Outcomes of Upfront Pancreatectomy with Venous Resection for Pancreatic Cancer: A Single-Center, Retrospective Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102572
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-06-10
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Interventions

Observation group:None

Sponsors

First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Clusion criteria:(1) Age between 18 and 80 years.(2) No evidence of distant metastasis confirmed by preoperative assessment.(3) Preoperative imaging studies suggestive of pancreatic cancer.(4) Signed surgical informed consent.(5) Preoperative assessment indicating resectable or borderline resectable pancreatic cancer according to the National Comprehensive Cancer Network (NCCN) guidelines.(6) No surgical contraindications identified during preoperative evaluation.(7) Intraoperative evaluation confirming no invasion of the celiac axis and/or superior mesenteric artery (SMA), and absence of distant metastasis.

Exclusion criteria

Exclusion criteria: Exclusion criteria:(1) Preoperative comprehensive assessment confirming distant metastasis of pancreatic cancer.(2) Pancreatic cancer assessed as unresectable according to the National Comprehensive Cancer Network (NCCN) guidelines.(3) Preoperative evaluation indicating inability to tolerate surgery.(4) Intraoperative evaluation revealing invasion of the celiac axis and/or superior mesenteric artery (SMA), or presence of distant metastasis.(5) Postoperative pathological examination confirming non-pancreatic carcinoma.(6) Patients or family members refusing surgical treatment, failure to sign or withdrawal of informed consent.

Design outcomes

Primary

MeasureTime frame
Overall survival;

Secondary

MeasureTime frame
Preoperative serum CA199 level;Adjuvant chemotherapy;Tumor differentiation;Age;

Countries

China

Contacts

Public ContactJianzhen Lin

First Affiliated Hospital of Nanjing Medical University, Nanjing

linjianzhen@njmu.edu.cn+86 151 8907 0624

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026